BUSINESS

Otsuka Eyes 3.5 Trillion Yen Sales by 2035 on New Growth Drivers

August 3, 2026
Otsuka Holdings aims to expand group revenue to 3.5 trillion yen by 2035, up from its newly revised FY2026 forecast of 2.73 trillion yen, by accelerating growth investments and bolstering its business portfolio, President and CEO Makoto Inoue said at…

To read the full story

Related Article

BUSINESS

By Philip Carrigan

Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…

By Hayate Horiguchi

The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…

By Kohei Hori

Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…

By Kohei Hori

Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…

By Takashi Ebisawa

Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…